Sirio Pharma Co., Ltd. Stock price

Equities

300791

CNE100003NB0

Food Processing

End-of-day quote Shenzhen S.E. 06:00:00 2024-02-21 pm EST 5-day change 1st Jan Change
31.28 CNY -0.16% Intraday chart for Sirio Pharma Co., Ltd. +1.33% -9.75%
Sales 2023 * 3.61B 501M Sales 2024 * 4.31B 599M Capitalization 5.68B 789M
Net income 2023 * 259M 35.99M Net income 2024 * 378M 52.53M EV / Sales 2023 * 1.57 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 1.32 x
P/E ratio 2023 *
21.8 x
P/E ratio 2024 *
15 x
Employees 2,193
Yield 2023 *
1.37%
Yield 2024 *
1.95%
Free-Float 27.27%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Sirio Pharma Co., Ltd.'s Equity Buyback Plan announced on September 15, 2023. CI
Sirio Pharma Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Certain A-Shares of Sirio Pharma Company Limited are subject to a Lock-Up Agreement Ending on 25-SEP-2023. CI
Sirio Pharma Co., Ltd.(XSEC:300791) added to S&P Global BMI Index CI
Sirio Pharma Co., Ltd. announces an Equity Buyback for CNY 40 million worth of its shares. CI
Sirio Pharma Co., Ltd. authorizes a Buyback Plan. CI
Sirio Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sirio Pharma Co., Ltd. Announces Implementation of Cash Dividend for the Year 2022, Payable on June 07, 2023 CI
Sirio Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sirio Pharma Co., Ltd. Proposes Profit Distribution Proposal of Cash Dividend for the Year 2022 CI
Sirio Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sirio Pharma Co., Ltd.(XSEC:300791) dropped from S&P Global BMI Index CI
Sirio Pharma Cancels Planned 1.35 Billion Yuan Share Sale to Fund Aquisition MT
Sirio Pharma Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Sirio Pharma Co., Ltd. acquired 80% stake in Best Formulations Inc. from m Eugene C. Ung, Kelly C. Ung, Charles C. Ung, Peak Trust Company-NV, Jeffrey A. Goh, and Joy S. Hsu. CI
More news
1 day-0.16%
1 week+1.33%
Current month+8.61%
1 month+2.96%
3 months-5.78%
6 months+14.20%
Current year-9.75%
More quotes
1 week
29.40
Extreme 29.4
32.39
1 month
25.11
Extreme 25.11
32.39
Current year
25.11
Extreme 25.11
36.00
1 year
24.24
Extreme 24.24
39.77
3 years
21.33
Extreme 21.33
69.50
5 years
20.36
Extreme 20.36
83.08
10 years
20.36
Extreme 20.36
83.08
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 15-03-31
Director of Finance/CFO 41 23-02-15
Director/Board Member 54 15-03-31
Members of the board TitleAgeSince
Director/Board Member 55 21-07-06
Director/Board Member 60 21-07-06
Chief Executive Officer 59 15-03-31
More insiders
Date Price Change Volume
24-02-22 31.28 -0.16% 470,286
24-02-21 31.33 +1.56% 860,691
24-02-20 30.85 -2.65% 665,942

End-of-day quote Shenzhen S.E., February 21, 2024

More quotes
Sirio Pharma Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of nutritional health food. The Company's main products include soft capsules, tablets, powders, soft candy, hard capsules and oral liquids. The Company's own brand is WEWOW nutritional health food. The Company distributes its products both in the domestic market and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31.28 CNY
Average target price
38.88 CNY
Spread / Average Target
+24.28%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Sirio Pharma Co., Ltd. - Shenzhen S.E.
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer